NLRC5, a promising new entry in tumor immunology
The recent use of T cell-based cancer immunotherapies, such as adoptive T-cell transfer and checkpoint blockade, yields increasing clinical benefit to patients with different cancer types. However, decrease of MHC class I expression is a common mechanism transformed cells take advantage of to evade...
Tallennettuna:
| Päätekijät: | , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BMJ Publishing Group
2016-11-01
|
| Sarja: | Journal for ImmunoTherapy of Cancer |
| Linkit: | https://jitc.bmj.com/content/4/1/39.full |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|